Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Drug Resistance

  Free Subscription

Articles published in J Virol

Retrieve available abstracts of 20 articles:
HTML format

Single Articles

    March 2022
  1. JIANG L, Samant N, Liu P, Somasundaran M, et al
    Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y.
    J Virol. 2022;96:e0198221.
    PubMed     Abstract available

    January 2022

  2. Articles of Significant Interest In This Issue.
    J Virol. 2022;96:e0199121.

  3. MURER L, Petkidis A, Vallet T, Vignuzzi M, et al
    Chemical Evolution of Rhinovirus Identifies Capsid-Destabilizing Mutations Driving Low-pH-Independent Genome Uncoating.
    J Virol. 2022;96:e0106021.
    PubMed     Abstract available

    November 2021
  4. KHATUN M, Kumar K, Baidya A, Mondal RK, et al
    Variability in the response of HBV D-subgenotypes to antiviral therapy: designing pan D-subgenotypic reverse transcriptase inhibitors.
    J Virol. 2021 Nov 3:JVI0180021. doi: 10.1128/JVI.01800.
    PubMed     Abstract available

    September 2021
  5. LEVINE CB, Mire CE, Geisbert TW
    Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System.
    J Virol. 2021;95:e0064321.
    PubMed     Abstract available

    June 2021
  6. NAKAJIMA S, Watashi K, Kato T, Muramatsu M, et al
    Biochemical and structural properties of entecavir-resistant hepatitis B virus polymerase with L180M/M204V mutations.
    J Virol. 2021 Jun 2:JVI0240120. doi: 10.1128/JVI.02401.
    PubMed     Abstract available

    May 2021
  7. WALTER M, Perrone R, Verdin E
    Targeting conserved sequences circumvents the evolution of resistance in a viral gene drive against human cytomegalovirus.
    J Virol. 2021 May 19. pii: JVI.00802-21. doi: 10.1128/JVI.00802.
    PubMed     Abstract available

    April 2021
  8. MORI K, Ohniwa RL, Takizawa N, Naito T, et al
    Development of a Genetically Stable Live Attenuated Influenza Vaccine Strain using an Engineered High-Fidelity Viral Polymerase.
    J Virol. 2021 Apr 7. pii: JVI.00493-21. doi: 10.1128/JVI.00493.
    PubMed     Abstract available

    October 2020
  9. LEE J, Parvathareddy J, Yang D, Bansal S, et al
    Emergence and Magnitude of ML336 Resistance in Venezuelan Equine Encephalitis Virus Depend on the Microenvironment.
    J Virol. 2020;94.
    PubMed     Abstract available

  10. JEONG JH, Choi WS, Antigua KJC, Choi YK, et al
    In vitro profiling of laninamivir-resistant substitutions in N3 to N9 avian influenza neuraminidase subtypes and their association with in vivo susceptibility.
    J Virol. 2020 Oct 14. pii: JVI.01679-20. doi: 10.1128/JVI.01679.
    PubMed     Abstract available

    September 2020
  11. PINKERT S, Kopp A, Bruckner V, Fechner H, et al
    Single-Point Mutations within the Coxsackie B Virus Receptor-Binding Site Promote Resistance against Soluble Virus Receptor Traps.
    J Virol. 2020;94.
    PubMed     Abstract available

    August 2020
  12. ST BERNARD L, Abolade J, Mohri H, Markowitz M, et al
    Drug-resistance mutation frequency of SGA-derived HIV-1 polymerase genomes in the CSF and plasma of HIV-1-infected individuals under non-suppressive therapy.
    J Virol. 2020 Aug 5. pii: JVI.01824-19. doi: 10.1128/JVI.01824.
    PubMed     Abstract available

    July 2020
  13. KEMPF BJ, Watkins CL, Peersen OB, Barton DJ, et al
    An Extended Primer Grip of Picornavirus Polymerase Facilitates Sexual RNA Replication Mechanisms.
    J Virol. 2020;94.
    PubMed     Abstract available

    May 2020
  14. MEDIOUNI S, Jablonski JA, Tsuda S, Barsamian A, et al
    Oregano oil and its principal component carvacrol inhibit HIV-1 fusion into target cells.
    J Virol. 2020 May 27. pii: JVI.00147-20. doi: 10.1128/JVI.00147.
    PubMed     Abstract available

    January 2020
  15. MELODY K, Roy CN, Kline C, Cottrell ML, et al
    Long-acting rilpivirine (RPV LA) pre-exposure prophylaxis does not inhibit vaginal transmission of RPV-resistant HIV-1 nor select for high frequency drug resistance in humanized mice.
    J Virol. 2020 Jan 22. pii: JVI.01912-19. doi: 10.1128/JVI.01912.
    PubMed     Abstract available

    December 2019
  16. HERNANDEZ MM, Fahrny A, Jayaprakash A, Gers-Huber G, et al
    Impact of suboptimal APOBEC3G neutralization on the emergence of HIV drug resistance in humanized mice.
    J Virol. 2019 Dec 4. pii: JVI.01543-19. doi: 10.1128/JVI.01543.
    PubMed     Abstract available

    August 2019
  17. WENSEL D, Sun Y, Davis J, Li Z, et al
    GSK3732394: A multi-specific inhibitor of HIV entry.
    J Virol. 2019 Aug 2. pii: JVI.00907-19. doi: 10.1128/JVI.00907.
    PubMed     Abstract available

    March 2019
  18. ZHUANG M, Vassell R, Yuan C, Keller PW, et al
    Mutations that increase the stability of the post-fusion gp41 conformation of the HIV-1 envelope glycoprotein are selected by both an X4 and R5 HIV-1 virus to escape fusion inhibitors corresponding to heptad repeat 1 of gp41, but the gp120 adaptive mu
    J Virol. 2019 Mar 20. pii: JVI.00142-19. doi: 10.1128/JVI.00142.
    PubMed     Abstract available

  19. BOYER PL, Melody K, Smith SJ, Dunn LL, et al
    Two Co-Selected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Non-nucleoside RT Inhibitors and Nucleoside Analogs.
    J Virol. 2019 Mar 20. pii: JVI.00224-19. doi: 10.1128/JVI.00224.
    PubMed     Abstract available

  20. ZHU Y, Chong H, Yu D, Guo Y, et al
    Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    J Virol. 2019 Mar 13. pii: JVI.02312-18. doi: 10.1128/JVI.02312.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.